Cambrex将爱荷华植物扩大120M, 将美国药物成分生产能力提高40%。 Cambrex expands Iowa plant by $120M, boosting U.S. drug ingredient production capacity by 40%.

Cambrex宣布将其在爱荷华州查尔斯城的API制造厂址扩大1.2亿美元,将生产能力增加40%,达到近100万公升,使其成为美国最大的独立设施。 Cambrex announced a $120 million expansion of its API manufacturing site in Charles City, Iowa, increasing capacity by 40% to nearly one million liters, making it the largest independent U.S. facility of its kind. 投资旨在加强国内药物供应的复原力,办法是促进生产活性药物成分和浸药治疗方法,支持重新上岸制造的努力。 The investment aims to strengthen domestic drug supply resilience by boosting production of active pharmaceutical ingredients and peptide therapeutics, supporting efforts to reshore manufacturing. 该项目以最近在爱荷华州、北卡罗来纳州和马萨诸塞州的扩展为基础,加强了极强的API、稀有疾病疗法和GMPpeptide制造能力。 The project builds on recent expansions in Iowa, North Carolina, and Massachusetts, enhancing capabilities in highly potent APIs, rare disease therapies, and GMP peptide manufacturing.